MethodCoverage window: current material reviewed through 2026-07-03 IST, emphasizing GitHub's July 2 Copilot changelog items; OpenAI's June 30 GeneBench-Pro research post and GPT-5.6 safety materials; Anthropic's June 30 Sonnet 5, Fable 5, and Claude Science posts as continuity checks; AWS forward-deployed engineering coverage from July 1-2; Nvidia neocloud infrastructure coverage from July 2; European Commission AI Act and GPAI Code pages updated June 25; InfoQ's late-June practitioner coverage; Thoughtworks Technology Radar Vol. 34; and recent agent-security research and reporting on prompt-injection role confusion.Evidence posture: GitHub, OpenAI, Anthropic, European Commission, AWS, InfoQ, Thoughtworks, and arXiv sources are primary, practitioner, analyst, or paper sources. AWS FDE, Nvidia neocloud, market, and role-confusion coverage rely on credible press where direct primary pages were not publicly indexed or were less specific than the reporting.
Primary sourcesOfficial company, regulator, project, or release-note pages.
12Credible pressReported coverage used to cross-check business and market claims.
6Analyst contextSpecialist interpretation, policy tracking, or market analysis.
1Community signalPractitioner or open community material used as weak signal only.
0Research papersAcademic or preprint evidence that needs production validation.
3Reference materialStable documentation, benchmark pages, or background sources.
0High confidence: GitHub, OpenAI, Anthropic, European Commission, AWS, InfoQ, Thoughtworks, and arXiv items are directly sourced from primary, practitioner, analyst, or paper pages reviewed during the run.
Medium confidence: AWS forward-deployed engineering, Nvidia neocloud financing, role-confusion research coverage, and market context rely partly on credible press summaries; terms, adoption pace, and financial exposure may change quickly.
Evidence gap: Vendor claims about AI productivity, scientific-agent performance, neocloud utilization, and deployment speed still need independent customer evidence, repeatable benchmarks, and longitudinal cost data.